ANT-045 / Antikor Biopharma - LARVOL DELTA

ANT-045: Demonstrating the promise of better penetrating, safer Antibody Fragment Drug-Conjugates (EORTC-NCI-AACR 2024) - "Complete cures were seen at doses as low as 0.5mg/kg (4 doses, once/week) demonstrating superiority to Phase 2 developmental benchmark ADC ABBV399 (telisotuzumab vedotin). Conclusions ANT-045 represents the next generation of ADC with a superior solid tumour penetrating and safety profile. Clinical evaluation is planned for 2026."

Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer

Gastric cancerantibody fragment drug-conjugates (FDCs): Applying a successful concept to solid tumours (AACR 2023) - "ANT-043 has pM potencies in a range of HER2-expressing cell-lines, including trastuzumab-resistant models, excellent tumour ablation effects in breast, ovarian and gastric cancer xenograft models and superior tolerability compared to an ADC in rat toxicology studies at a dose of 1mg/kg/weekly. ANT-045 has excellent in vitro cell-kill potency (pM IC50s) and excellent stability and superior in vivo tumour cure efficacy, compared to a leading clinical stage benchmark ADC. This presentation will focus on Antikor’s FDC discovery platform (stable high-DAR scFv-display libraries, tailored linker-payloads and design features) that has the potential to generate first-in-class products for difficult to treat solid tumours for patient benefit and promising to succeed where ADCs have failed to make an impact."

Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • Urethral Cancer

Gastric cancer antibody fragment drug-conjugates (FDCs): Succeeding in solid tumors where ADCs fail (AACR 2022) - "ANT-043 has pM potencies in a range of HER2-expressing cell-lines, including trastuzumab-resistant models, excellent tumor ablation effects in breast, ovarian and gastric cancer xenograft models and superior tolerability compared to an ADC in rat toxicology studies at a dose of 1mg/kg/weekly. ANT-045 has excellent in vitro cell-kill potency (pM IC50s) and excellent stability and superior in vivo tumor cure efficacy, compared to a leading clinical stage benchmark ADC. This presentation will focus on Antikor’s FDC discovery platform (stable high-DAR scFv-display libraries, tailored linker-payloads and design features) that has the potential to generate first-in-class products for difficult to treat solid tumors for patient benefit and promising to succeed where ADCs have failed to deliver."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor

[VIRTUAL] Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors (AACR 2021) - "This presentation will focus on ANT-045’s remarkable development and show that this FDC demonstrates superior efficacy and tolerability compared to an ADC when equated on an equi-mass, equi-molar and equi-payload basis. ANT-045 could be used to switch ‘immunologically-cold’ tumour ‘hot’ to benefit from checkpoint inhibitor therapy and data will be presented to support this concept."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor